AlphAIAlphAI — Financial news for AI agents
MSNMAY 213 min read$BOLT

Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates

Bolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 million, significantly lower than the $5.53 million expected.

Original reporting
MSN
Published May 21, 2026, 3:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 21, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BOLT
Bearish
medium confidence
Mentioned
$BOLT
AlphAI data visualization · based on MSN
Decision brief

The 30-second read

$BOLTBearishMed
01

Why it matters

The earnings miss has led to increased bearish sentiment, likely causing a decline in stock price. Sector-wide effects may include increased volatility in biotech indices.

02

Market read

High relevance for biotech investors and traders focusing on sector momentum and earnings reports.

03

What to watch

Potential positive catalysts such as pipeline advancements or strategic collaborations not reflected in current earnings

Timing: Immediate to short-term trading window

Background

Bolt Biotherapeutics operates in the biotech sector, focusing on immuno-oncology therapies. Recent earnings report showed wider losses and revenue shortfalls, raising concerns about short-term performance.

Company-level read

Ticker impact

$BOLTBearishMedium confidence
Context

Primary focus due to recent earnings report

Expected impact

Short-term decline expected; potential rebound if fundamentals improve

Evidence & confidence

Earnings miss and negative sentiment suggest downward pressure, but biotech stocks can be volatile with potential for recovery based on future developments.

Market effects

Sector

Negative impact on biotech sector indices; potential spillover to life sciences stocks

Regional

Limited regional impact; company primarily US-focused

Global

Moderate; biotech sector is globally interconnected but specific to US market

Counterpoint

What could challenge this read

The earnings miss may be a temporary setback; company could rebound with upcoming clinical trial results or partnerships

Key entities

  • Company
    Bolt Biotherapeutics

    A biotech firm specializing in immuno-oncology therapies.

Read at source← All news

Related articles

SEP 17
$LCIDMed

Lucid and Bolt Plan 25,000 Autonomous EVs in Europe

Lucid Motors and Bolt plan to develop 25,000 autonomous EVs for Europe using Lucid's Midsize platform. The vehicles aim for SAE Level 4 autonomy, with Bolt operating the fleet. Lucid also partners with Uber and Nuro for U.S. robotaxis. Commercial deployment timing is unclear due to Midsize program delays.

electriccarsreport.com6 min
AUG 11
$BOLTMed

Bolt Biotherapeutics, Inc. (BOLT): Results of Operations and Financial Condition

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results • Cash b

SEC EDGAR 8-K3 min
SEP 17
$LMTHighAI 9/10

US approves over $24 billion F-35 fighter jet sale to Saudi Arabia

The U.S. approved a potential $24.3B sale of 48 Lockheed Martin F-35 fighter jets to Saudi Arabia, including engines and support equipment. The sale aims to bolster Saudi Arabia's defense capabilities and interoperability with U.S. forces, but faces objections from Israel. The deal is part of broader defense cooperation and Saudi Arabia's military modernization efforts under Vision 2030.

dailysabah.com2 min
SEP 17
$LMTHighAI 9/10

US clears way for $24.3 billion military aircraft sale to Saudi Arabia

The US State Department approved a $24.3 billion sale of 48 F-35 fighter jets and related equipment to Saudi Arabia, involving Lockheed Martin and Pratt & Whitney. The sale aims to support US foreign policy and regional stability, according to the department. Congress has 30 days to review the deal. The announcement follows Saudi Arabia's request for US military assistance against Yemen's Houthis, with ongoing diplomatic discussions.

tribune.com.pk2 min